Transcriptomic profiling revealed FZD10 as a novel biomarker for nasopharyngeal carcinoma recurrence

• Published in: Frontiers in oncology Vol. 12; p. 1084713
• Main Authors: Tulalamba, Warut, Ngernsombat, Chawalit, Larbcharoensub, Noppadol, Janvilisri, Tavan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 20.01.2023
• Subjects: biomarkers; microarray; nasopharyngeal carcinoma; Oncology; recurrence; transcriptome; Wnt signaling; recurrence; Wnt signaling; microarray; nasopharyngeal carcinoma; biomarkers; transcriptome
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2022.1084713

Nasopharyngeal carcinoma (NPC) is a type of cancers that develops in the nasopharynx, the very upper part of the throat behind the nose. NPC is typically diagnosed in later stages of the disease and has a high rate of recurrence due to the location of the tumor growth site. In this study, we compared the gene expression profiles of NPC tissues from patients with and without recurrence to identify potential molecular biomarkers of NPC recurrence. Microarrays were used to analyze the expression of genes in 15 NPC tissues taken at the time of diagnosis and at the site of recurrence following therapeutic treatment. Pathway enrichment analysis was used to examine the biological interactions between the major differentially expressed genes. The target identified was then validated using immunohistochemistry on 86 NPC tissue samples. Our data showed that the Wnt signaling pathway was enhanced in NPC tissues with recurrence. FZD10, a component of the Wnt signaling pathway, was significantly expressed in NPC tissues, and was significantly associated with NPC recurrence. Our study provides new insights into the pathogenesis of NPC and identifies FZD10 as a potential molecular biomarker for NPC recurrence. FZD10 may be a promising candidate for NPC recurrence and a potential therapeutic target.